DNA X (SONM) Earnings Analysis

DNA X (SONM) next reports earnings on 2026-08-17, consensus EPS 5.22 USD. Last quarter (2026-05-20) it missed with EPS -3.11 USD vs 5.04 USD est (-161.7%). It has beaten estimates in 2/7 recent quarters (29%). Trailing P/E -0.13.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SONM next report earnings?

Next earnings date2026-08-17
Consensus EPS estimate5.22 USD
Revenue estimate0.04B

SONM earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-20-3.11 USD5.04 USD-161.7%Miss
2026-01-30-10.97 USD10.97 USD-200%Miss
2025-10-31-3.86 USD5.4 USD-171.5%Miss
2025-08-08-10.97 USD0.72 USD-1623.6%Miss
2025-05-120.08 USD-0.13 USD+161.5%Beat
2025-04-02-4.33679 USD-0.4 USD-984.2%Miss
2024-08-09-1.41 USD-1.41 USD0%Beat

Beat rate: 2/7 (29%) over reported quarters with consensus data.

SONM valuation and analyst view

Trailing P/E-0.13
Trailing EPS-11.67922 USD
Price / book-47.86
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (3 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is DNA X (SONM)'s next earnings date?

DNA X is next scheduled to report on 2026-08-17, with a consensus EPS estimate of 5.22 USD and revenue estimate of 0.04B.

Did SONM beat earnings last quarter?

In its 2026-05-20 report, SONM posted EPS of -3.11 USD versus a 5.04 USD estimate — a miss of 161.7%.

What is SONM's earnings track record?

Over the last 7 reported quarters with consensus data, SONM beat estimates 2 times (29%).

What is SONM's current P/E ratio and EPS?

SONM trades at a trailing P/E of -0.13 on trailing EPS of -11.679223313864009 USD.

What do analysts rate SONM?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell).